Citations

Clear

70 citation(s) found for "Garrison, A".

S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
Dubinsky, Marla C. , D’Haens, Geert , Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, Samuel I., Garrison, Andrew, Dewit, Olivier , Juillerat, Pascal , Panaccione, Remo , Fujii, Toshimitsu , Anyanwu, Samuel, Doshi, Chirag, Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0000954280.83972.54 Get It

S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It

Meningomyelocele Reconstruction: Comparison of Repair Methods via Systematic Review
Leach, Garrison A., Roberts, Alexis-Danielle , O’Connor, Madeline J., Bristol, Ruth E., Mabee, Melinda K., Almader‐Douglas, Diana , Schaub, Timothy A., Almader-Douglas, Diana, Pflibsen, Lacey R. , O’Connor, Madeline J.

Mayo Clinic

Journal of Craniofacial Surgery | August 25, 2023 | Volume: 34 | Issue: 7 | Pages: 2040-2045

10.1097/scs.0000000000009675 | PMID 37622546 Get It

Purpose: The purpose of this article was to appraise the various methods of reconstruction for meningomyelocele (MMC) defects. Methods: A systematic review of the literature was performed to evaluate all reconstructions for MMC. The method of reconstruction was categorized by: primary closure with and without fascial flaps, random pattern flaps, VY advancement flaps (VY), perforator flaps, and myocutaneous flaps. Perforator flaps were subsequently subcategorized based on the type of flap. Results: Upon systematic review, 567 articles were screened with 104 articles assessed for eligibility. Twenty-nine articles were further reviewed and included for qualitative synthesis. Two hundred seventy patients underwent MMC repair. The lowest rates of major wound complications (MWC) were associated with myocutaneous and random pattern flaps. A majority of MWC was in the lumbrosacral/sacral region (87.5% of MWC). In this region, random patterns and perforator flaps demonstrated the lowest rate of MWC (4.5, 8.1%). Conclusions: Plastic surgery consultation should be strongly considered for MMC with defects in the lumbosacral/sacral region. Perforator flaps are excellent options for the reconstruction of these defects.
Prevention and Treatment of Nonfreezing Cold Injuries and Warm Water Immersion Tissue Injuries: A Supplement to the Wilderness Medical Society Clinical Practice Guidelines
Zafren, Ken , Hollis, Sarah, Weiss, Eric A., Danzl, Daniel F., Wilburn, Jessie , Kimmel, Nadia, Imray, Chris , Giesbrecht, Gordon G. , Tipton, Mike

Mayo Clinic

Wilderness & Environmental Medicine | May 3, 2023 | Volume: 34 | Issue: 2 | Pages: 172-181

10.1016/j.wem.2023.02.006 | PMID 37130771 Get It

We convened an expert panel to develop evidence-based guidelines for the evaluation, treatment, and prevention of nonfreezing cold injuries (NFCIs; trench foot and immersion foot) and warm water immersion injuries (warm water immersion foot and tropical immersion foot) in prehospital and hospital settings. The panel graded the recommendations based on the quality of supporting evidence and the balance between benefits and risks/burdens according to the criteria published by the American College of Chest Physicians. Treatment is more difficult with NFCIs than with warm water immersion injuries. In contrast to warm water immersion injuries that usually resolve without sequelae, NFCIs may cause prolonged debilitating symptoms, including neuropathic pain and cold sensitivity.
Warfarin Related Kidney Damage: A Confusing Case of Thrombophlebitis Masquerading as Infection
Samuelson, Brittanee J. , Matthew, Decker, Hannah, Scott, Garrison, Gregory M. , Brittanee, Samuelson , Garrison, Gregory M

Mayo Clinic

Journal of Primary Care & Community Health | March 18, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231159978 | PMID 36932865 Get It

Anticoagulant-related nephropathy (ARN) is a rare, newly recognized cause of acute kidney injury and significant but underdiagnosed complication of anticoagulation therapy. ARN occurs in patients taking oral anticoagulant therapy most often warfarin or a novel oral anticoagulant (NOAC). It is a potentially devastating disorder with serious renal consequences and increased all-cause mortality. Anticoagulant-related nephropathy presents as an acute kidney injury (AKI) in the setting of a supratherapeutic INR with profuse glomerular hemorrhage seen as renal tubules filled with red cells and red cell casts on renal biopsy. Being that millions of Americans are on warfarin, a thorough understanding and awareness of the clinical presentation, diagnosis, and therapeutic interventions are crucial to protecting the renal function, lowering all-cause mortality and optimizing treatment. Our goal is to provide education on a newly recognized form of AKI and significant but underdiagnosed complication of anticoagulation therapy.
P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Cohen, Benjamin L., Ha, Christina , Dubcenco, Elena, Lacerda, Ana P. , Marced, E, Oomen, Jessica, Garrison, A, Vermeire, Séverine , Danese, Silvio , Magro, Fernando , Chen, Y, Marced, Elena, Peyrin‐Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i510-i513

10.1093/ecco-jcc/jjac190.0509 Get It

Abstract Background Improvement in clinical outcomes and normalisation of objective markers of inflammation, high-sensitivity C-reactive protein (hs-CRP) and faecal calprotectin (FCP), are considered treatment targets per STRIDE-II guidelines.1 We evaluated the effect of the oral selective Janus kinase inhibitor upadacitinib (UPA) on changes in hs-CRP, FCP, and clinical outcomes in patients with Crohn’s disease (CD). Methods In 2 phase 3, randomized, double-blind, placebo-controlled induction studies (U-EXCEL, NCT03345849; U-EXCEED, NCT03345836), patients with moderate-to-severe CD received 12-week treatment with UPA 45 mg (UPA45) once daily (QD) or placebo (PBO). Patients with clinical response to UPA45 were rerandomised in U-ENDURE (NCT03345823) to receive 52-week maintenance treatment with UPA 30 mg QD (UPA30), UPA 15 mg QD (UPA15), or PBO. Endpoints included marker normalisation (hs-CRP ≤ 5 mg/L, FCP ≤ 250 µg/g) in patients with elevated baseline marker levels, normal marker and clinical remission by Crohn’s Disease Activity Index (CDAI < 150) or very soft/liquid stool frequency (SF)/abdominal pain score (APS) (average daily SF ≤ 2.8 and average daily APS ≤ 1, neither greater than baseline), and ≥ 50% reduction from baseline in marker values with a decrease of at least 100 points in CDAI from baseline. Median changes from baseline in marker levels were also evaluated. Non-responder imputation with no special data handling for missing data due to COVID-19 was used. Results Of 1021 enrolled patients, 645 (63.2%) had elevated hs-CRP (> 5 mg/L) and 750 (73.5%) had elevated FCP (> 250 µg/g) levels at baseline. Significantly greater proportions of patients with elevated baseline marker levels achieved normalisation with UPA compared with PBO at week 12 (Fig 1A/B) and week 52 (Fig 2A/B; nominal P < .001 for all). Decreases in marker levels from baseline with UPA were observed as early as week 2 and were significantly greater than with PBO through week 12 (Fig 1C) and week 52 (Fig 2C; nominal P < .001 for all). Patients achieved clinical endpoints and improvements in markers at significantly higher rates with UPA45 vs PBO at week 12 (Fig 1D–F) and with UPA15 and UPA30 vs PBO at week 52 (Fig 2D–F; P < .001 for all). The safety profile of UPA in CD was previously reported and no new safety concerns were identified. Conclusion Improvements in clinical endpoints and normalisation of objective markers of inflammation were achieved as early as week 2 with UPA45 induction and sustained with UPA15 and UPA30 maintenance therapy in patients with CD. Median changes in hs-CRP and FCP with UPA support continued improvement of inflammation up to week 52. 1. Turner D., et al. Gastroenterology. 2021;160(5):1570–1583.
DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
Dubinsky, M, D’Haens, Geert , Panaccione, Remo, FUJII, Teruko, Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, S., Doshi, C, Garrison, A, Liu, J, Dewit, Olivier , Juillerat, Pascal , Mallick, M, Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i104-i106

10.1093/ecco-jcc/jjac190.0080 Get It

Abstract Background Corticosteroids (CS) may be used for induction of remission in Crohn’s disease (CD); however, side effects, toxicities, and low rates of mucosal healing may limit their long-term use. Safety and efficacy of upadacitinib (UPA), an oral selective Janus kinase inhibitor, were evaluated among patients with CD receiving UPA with CS at baseline in phase 3 clinical trials. Methods In 2 phase 3 studies (U-EXCEL, NCT03345849; U-EXCEED, NCT03345836), patients with moderate-to-severe CD were randomized to 12-week induction with UPA 45 mg once daily (QD) or placebo (PBO). Patients who achieved clinical response to UPA 45 mg were rerandomized in U-ENDURE (NCT03345823) to UPA 30 mg QD, UPA 15 mg QD, or PBO for a 52-week maintenance period. Patients taking CS at baseline or week 0 of maintenance (end of induction) were included. A CS taper began at induction week 4 and continued during maintenance. Endpoints included the proportion of patients who discontinued CS use (CS-free) at week 12 or for ≥ 90 days prior to week 52, and achieved clinical remission by stool frequency/abdominal pain score or by Crohn’s Disease Activity Index (CDAI), enhanced clinical response, decrease of at least 100 points in CDAI from baseline, endoscopic remission, and endoscopic response at week 12 and week 52. CS daily dose (in prednisone equivalent doses) was recorded. Safety was assessed through induction and maintenance. Results Of 1021 patients evaluated, 358 (35.1%) were taking CS at baseline (mean daily prednisone equivalent dose, 23.0 mg). Greater changes from baseline in mean CS daily dose were observed with UPA vs PBO at induction week 12 (−17.3 mg vs −10.7 mg); these changes were sustained at maintenance week 52 (UPA 30 mg, −16.4 mg; UPA 15 mg, −17.4 mg; PBO, −14.7 mg). The proportion of patients who achieved a ≥ 50% reduction in CS daily dose was higher with UPA vs PBO at induction week 12 among patients taking CS at baseline (72.6% vs 48.4%) and at week 52 among patients taking CS at baseline or week 0 of maintenance (UPA 30 mg, 49.2%; UPA 15 mg, 44.4%; PBO, 11.1%). A significantly higher proportion of patients taking UPA vs PBO were CS-free and achieved clinical remission, clinical response, endoscopic response, and endoscopic remission at week 12 (Fig 1A) and week 52 (Fig 1B). Rates of adverse events (AEs), serious AEs, and discontinuation were comparable between groups (Table 1). Serious infections, opportunistic infections, and herpes zoster events were numerically higher with UPA vs PBO (Table 1). Conclusion Patients with CD taking CS were able to taper and discontinue their CS regimen and experience clinical and endoscopic improvements with UPA treatment during the induction and maintenance periods.
Clones of Alloreactive T Cells
Fathman, C. Garrison, Hengartner, H.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 121 | Issue: 4 | Pages: 1615-1615

10.4049/jimmunol.121.4.1615.b Get It

Abstract Previous observations from our lab and many others have suggested that MLR determinants are composed of I region gene products. We extended our original observations by studying the reactivities of responder cells obtained after in vitro primary stimulation (primed responder cells = PRC) with selected stimulator cells. These studies suggested that MLR determinants exist as “interaction” products of several I region genes which can act in cis- or trans- position. Furthermore, these studies suggested the existence of specific clones of PRC which could recognize unique F1 MLR determinants. Using serially restimulated PRC which had been in culture for over three months, we derived colonies of alloreactive cells (using soft agar cloning techniques) which have remarkably restricted reactivities. Studies with these “cloned” PRC supported our original premise concerning clones of unique F1 reactive PRC and suggested the existence of unique “homozygous” MLR determinants and clones of cells which specifically recognize such determinants.
Non-H-2 Linked Control of Low Versus High Responses of Antigen-Induced Lymph Node Cell Proliferation: Possible Role for Antigen-Presenting Cells
Fathman, C. Garrison, Tomasi, Thomas B., Suzuki, Koji A. O.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 123 | Issue: 4 | Pages: 1530-1534

10.4049/jimmunol.123.4.1530 Get It

Abstract Quantitative differences in the magnitude of antigen-induced proliferative responses of sensitized lymph node cells between low (C3H/Anf or C3H/Cr) and high (C3H/Hej or CBA/j) responder H-2k mice have been observed 1 to 2 weeks after in vivo sensitization with antigen (OVA, PPD, and GAT). We have shown that antigen presentation is less effective in the sensitized lymph node cell populations from low responder mice compared with those from high responder mice, suggesting that the number and/or functional status of antigen-presenting cells in the regional lymph nodes may be a key factor in determining the magnitude of antigen-induced proliferative responses. These data are consistent with the hypothesis that cell traffic after sensitization plays an important role in determining the immune responsiveness of lymph nodes.
Athletic disruptions caused by the COVID-19 pandemic negatively affect high school student-athletes social-emotional well-being
Collins, Dustin P., Sowders, John P., Blessman, Joseph D., McLachlan, Madison L., Garrison, Emily G., Kuisle, Mark, Asplund, Chad A., Garrison, Gregory M. , Garrison, Gregory M , Jagim, Andrew R. , Sowders, John, Miller, Nathaniel E.

Mayo Clinic

Medicine | December 27, 2022 | Volume: 101 | Issue: 51 | Pages: e31890

10.1097/md.0000000000031890 | PMID 36595767 Get It

To examine whether high school student-athletes who experienced more COVID-19 disruptions had increased anxiety, increased dejection, increased anger, decreased excitement, and decreased happiness as measured by the validated Sports Emotion Questionnaire (SEQ). During the COVID-19 pandemic high school student-athletes faced disruptions which resulted in cancelation of competitions, reduced in-person training sessions, and quarantine of athletes. The impact of these disruptions on the mental health and well-being of student-athletes is unknown. An anonymous cross-sectional online survey was electronically distributed to high school student-athletes in one school district during the spring of the 2020 to 21 academic year. Basic demographic questions, sport information, and personal and team disruptions were collected. Multivariate linear regression was used to assess correlation between each emotional domain on the SEQ with independent variables such as personal or teammate quarantines, cancelations, season, sport gender, indoor or outdoor location, and level of competition. 125 surveys were returned representing 28 different sports. Student-athletes who were personally quarantined (22.4%) during their athletic season experienced greater dejection (β = 0.78, P = .003) and greater anger (β = 0.78, P = .005). Those with teammates quarantined (61.6%) experienced more anxiety (β = 0.30, P = .048). Spring sports, which faced fewer restrictions, were associated with less anger (β = −0.48, P = .048). Student-athletes who were directly affected by COVID-19 disruptions experienced increased anxiety, more dejection, and more anger. Public health authorities and school districts should minimize disruptions to athletic participation using established COVID-19 safety protocols to avoid causing harm to athletes’ social-emotional well-being. If athletics must be disrupted, student-athletes should receive wellness support and virtual or remote training options.